Mohamed Bouattour

18PUBLICATIONS
121CO-AUTHORS
Haematological tumoursMolecular targetsCancer therapy (excl. chemotherapy and radiation therapy)ChemotherapyOncology and carcinogenesis not elsewhere classified
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (18)

|Sep 21, 2026
Current Perspectives on the Use of Adjuvant Pembrolizumab for Hepatocellular Carcinoma.

|Jul 24, 2026
Prognostic Impact of Concomitant Genomic Alterations in FGFR2-Positive Cholangiocarcinoma Treated With Pemigatinib.

|Apr 20, 2026
Long-term Survival and Cure Fraction in Patients with Advanced Hepatocellular Carcinoma under Immunotherapy in Randomized Controlled Trials and Real-world Data.

|Jul 09, 2025
Sunitinib as Second-Line Treatment in Advanced Intrahepatic Cholangiocarcinoma: Results From the SUN-CK GERCOR Phase II Trial.

Louis Gros, Mohamed Bouattour, Clément Dumont

|Jun 21, 2025
Regorafenib plus modified gemcitabine-oxaliplatin in patients with advanced biliary tract cancer. The randomized phase Ib/II BREGO study.

Jean-Frédéric Blanc, Mohamed Bouattour, Ludovic Gauthier

|Jul 11, 2024
Evolution of liver function during immune checkpoint inhibitor treatment for hepatocellular carcinoma.

Katharina Pomej, Lorenz Balcar, Sabrina Sidali

Pageof 3

Frequent Collaborators

3 joint publications

Jean-Charles Nault

2 joint publications

Katharina Pomej

2 joint publications

Maxime Ronot

2 joint publications

Thomas Reiberger